WALTHAM, Mass.--(BUSINESS WIRE)--
Thermo Fisher Scientific Inc. (NYSE: TMO) announced today that it has
priced an offering of €1.0 billion aggregate principal amount of its
0.750% senior notes due 2024 and €600 million aggregate principal amount
of its 1.375% senior notes due 2028 at the issue prices of 99.122% of
the principal amount and 99.748% of the principal amount, respectively.
The issuance of the notes is expected to close on or about September 12,
2016, subject to customary closing conditions. The notes will pay
interest on an annual basis.
Thermo Fisher intends to use the net proceeds of the offering to finance
a portion of the estimated $4.2 billion purchase price for its
acquisition of FEI Company and to pay certain associated costs. The FEI
acquisition is expected to close by December 31, 2016, subject to the
satisfaction of customary closing conditions, including applicable
The joint book-running managers for the offering are J.P. Morgan
Securities plc, Barclays Bank PLC, Mizuho International plc and Morgan
Stanley & Co. International plc.
The offering is being made pursuant to an effective registration
statement on Form S-3, as amended by the post-effective amendment
thereto (including a prospectus), filed with the U.S. Securities and
Exchange Commission (the “SEC”). Prospective investors should read the
prospectus forming a part of that registration statement and the
prospectus supplement related to the offering and the other documents
that the company has filed with the SEC for more complete information
about the company and this offering. These documents are available at no
charge by visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, Thermo Fisher, the underwriters or any dealer
participating in this offering will arrange to send you the prospectus
if you request it by calling J.P. Morgan Securities plc collect at +44
207-134-2468; by calling Barclays Bank PLC toll-free at 1-888-603-5847;
by calling Mizuho International plc toll-free at +44 207-090-6929; or by
calling Morgan Stanley & Co. International plc toll-free at
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the notes, nor shall there be any offer,
solicitation or sale of the notes in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such jurisdiction.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements about the company’s intended
use of proceeds. These statements involve a number of risks and
uncertainties that could cause actual results to differ materially from
currently anticipated results, including risks and uncertainties
relating to capital markets conditions and completion of the offering.
Additional important factors and information regarding Thermo Fisher’s
business that could cause actual results to differ materially from those
indicated by such forward-looking statements are set forth in the
prospectus and prospectus supplement dated September 7, 2016 related to
the offering, which is on file with the SEC and available in the
“Investors” section of our website under the heading “SEC Filings,” and
the documents incorporated by reference into the prospectus and
prospectus supplement. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if circumstances change and, therefore, you
should not rely on these forward-looking statements as representing our
views as of any date subsequent to today.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160907006925/en/
Source: Thermo Fisher Scientific Inc.